FDA Reshapes Drug Approvals, AI Initiative and Delayed Camizestrant Review Impact AstraZeneca

The U.S. Food and Drug Administration has introduced a revised drug approval standard that replaces the classic requirement of two pivotal trials with one robust pivotal trial supplemented by additional confirmatory evidence, a change that could reduce the time and resources needed to bring new drugs to market. The agency is also launching an artificial intelligence initiative to evaluate clinical trial results in real time, and it has extended the review of AstraZeneca's breast cancer drug camizestrant.

Under the new approval standard, pharmaceutical companies may need to conduct only one pivotal trial, which could significantly impact AstraZeneca and other major players by accelerating the time it takes for promising treatments to reach the market.

Separately, the FDA is looking to deploy AI to achieve real-time evaluation of clinical trial results. The agency has tapped AstraZeneca and Amgen to conduct two proof-of-concept trials and is launching a broader pilot program, with industry stakeholder input sought until May 29. Currently, drugmakers conduct clinical trials in partnership with medical centers, with results compiled manually from electronic health records for submission to the FDA, a process that can last for several years. The FDA's commissioner said the 'modern approach' means the agency will be able to view safety profiles and trial target data in real time as the studies progress. In a statement, the agency said: 'With improvements in AI and data science, sponsors and trial sites have the opportunity to conduct real-time trials in a way that enhances safety monitoring and radically increases efficiency.'

As part of the proof-of-concept trials, AstraZeneca is conducting a Phase 2 multi-site study called TRAVERSE for patients with mantle cell lymphoma who have not received any prior treatment. Amgen is planning a Phase 1b STREAM-SCLC trial for patients with limited-stage small cell lung carcinoma.

In addition, the FDA has extended the PDUFA date for AstraZeneca's New Drug Application for camizestrant, an oral selective estrogen receptor degrader, to review additional data. The FDA's Oncologic Drugs Advisory Committee did not reach a majority vote in favor of switching to camizestrant after detecting an ESR1 mutation in the SERENA-6 Phase III trial. AstraZeneca has provided further analyses requested by the FDA, including additional ctDNA clearance data. Camizestrant has been approved in the UAE and Saudi Arabia, with regulatory applications under review in Japan and other countries.

Meanwhile, a key FDA official known for contentious decisions, including declining Moderna's proposal for a new mRNA flu vaccine and rejecting a review request for a Huntington's treatment by UniQure, will depart his position at the end of April, according to a Health and Human Services spokesperson. The departure could have significant implications for pharmaceutical companies, including AstraZeneca.

AstraZeneca, formed from the merger of Astra of Sweden and Zeneca of the United Kingdom in 1999, is a prominent player in the healthcare sector, with the United States accounting for nearly one-third of its sales. The company reported revenue of $58.74 billion, a three-year revenue growth rate of 6.4%, an operating margin of 23.42%, a net margin of 17.45%, and a current ratio of 0.94. Its dividend yield is near a 10-year low.